Noncoding RNAs play important roles in cancer biology, providing potential targets for cancer intervention. As a new class of endogenous noncoding RNAs, circular RNAs (circRNAs) have been recently identified in cell development and function, and certain types of pathological responses, generally acting as a microRNA (miRNA) sponge to regulate gene expression. Identifying the deregulated circRNAs and their roles in cancer has attracted much attention. However, the expression profile and function of circRNAs in human hepatocellular carcinoma (HCC) remain to be investigated. Here, we analyzed the expression profile of human circRNAs in HCC tissues and identified circMTO1 (mitochondrial translation optimization 1 homologue; hsa_circRNA_0007874/hsa_circRNA_104135) as one circRNA significantly down-regulated in HCC tissues. HCC patients with low circMTO1 expression had shortened survival. By using a biotin-labeled circMTO1 probe to perform RNA in vivo precipitation in HCC cells, we identified miR-9 as the circMTO1-associated miRNA. Furthermore, silencing of circMTO1 in HCC could down-regulate p21, the target of oncogenic miR-9, resulting in the promotion of HCC cell proliferation and invasion. In addition, the tumor-promoting effect of circMTO1 silencing was blocked by miR9 inhibitor. Intratumoral administration of cholesterol-conjugated circMTO1 small interfering RNA promoted tumor growth in HCC-bearing mice in vivo. Conclusion: circMTO1 suppresses HCC progression by acting as the sponge of oncogenic miR-9 to promote p21 expression, suggesting that circMTO1 is a potential target in HCC treatment. The decrease of circMTO1 in HCC tissues may serve as a prognosis predictor for poor survival of patients. ( (1,2) circRNAs are conserved and stable, and numerous circRNAs seem to be specifically expressed in a given cell type or Abbreviations: AFP, alfa-fetoprotein; ARID1B, AT-rich interaction domain 1B; circRNAs, circular RNAs; ELISA, enzyme-linked immunosorbent assay; FAM13B, family with sequence similarity 13 member B; FARP2, FERM, ARH/RhoGEF and pleckstrin domain protein 2; FISH, fluorescence in situ hybridization; HCC, hepatocellular carcinoma; ISH, in situ hybridization; kaps, K-adaptive partitioning statistical; miRNA, microRNA; MMP2, matrix metalloproteinase 2; MTO1, mitochondrial translation optimization 1 homologue; PBS, phosphate-buffered saline; PCNA, proliferating cell nuclear antigen; RIP, RNA in vivo precipitation; siRNA, small interfering RNA.
Noncoding RNAs play important roles in cancer biology, providing potential targets for cancer intervention. As a new class of endogenous noncoding RNAs, circular RNAs (circRNAs) have been recently identified in cell development and function, and certain types of pathological responses, generally acting as a microRNA (miRNA) sponge to regulate gene expression. Identifying the deregulated circRNAs and their roles in cancer has attracted much attention. However, the expression profile and function of circRNAs in human hepatocellular carcinoma (HCC) remain to be investigated. Here, we analyzed the expression profile of human circRNAs in HCC tissues and identified circMTO1 (mitochondrial translation optimization 1 homologue; hsa_circRNA_0007874/hsa_circRNA_104135) as one circRNA significantly down-regulated in HCC tissues. HCC patients with low circMTO1 expression had shortened survival. By using a biotin-labeled circMTO1 probe to perform RNA in vivo precipitation in HCC cells, we identified miR-9 as the circMTO1-associated miRNA. Furthermore, silencing of circMTO1 in HCC could down-regulate p21, the target of oncogenic miR-9, resulting in the promotion of HCC cell proliferation and invasion. In addition, the tumor-promoting effect of circMTO1 silencing was blocked by miR9 inhibitor. Intratumoral administration of cholesterol-conjugated circMTO1 small interfering RNA promoted tumor growth in HCC-bearing mice in vivo. Conclusion: circMTO1 suppresses HCC progression by acting as the sponge of oncogenic miR-9 to promote p21 expression, suggesting that circMTO1 is a potential target in HCC treatment. The decrease of circMTO1 in HCC tissues may serve as a prognosis predictor for poor survival of patients. ( characterized by covalently closed loop structures with neither 5 0 to 3 0 polarity nor polyadenylated tail. (1, 2) circRNAs are conserved and stable, and numerous circRNAs seem to be specifically expressed in a given cell type or Abbreviations: AFP, alfa-fetoprotein; ARID1B, AT-rich interaction domain 1B; circRNAs, circular RNAs; ELISA, enzyme-linked immunosorbent assay; FAM13B, family with sequence similarity 13 member B; FARP2, FERM, ARH/RhoGEF and pleckstrin domain protein 2; FISH, fluorescence in situ hybridization; HCC, hepatocellular carcinoma; ISH, in situ hybridization; kaps, K-adaptive partitioning statistical; miRNA, microRNA; MMP2, matrix metalloproteinase 2; MTO1, mitochondrial translation optimization 1 homologue; PBS, phosphate-buffered saline; PCNA, proliferating cell nuclear antigen; RIP, RNA in vivo precipitation; siRNA, small interfering RNA. developmental stage. (3, 4) These cell-type-or developmental-stage-specific expression patterns indicate that circRNAs may play important roles in many physiological and pathophysiological processes. Natural endogenous circRNAs are inherently resistant to exonucleolytic RNA decay and contain selectively conserved microRNA (miRNA) target sites. So, circRNAs can serve as efficient miRNA sponges, interacting with miRNA to regulate gene expression. The dysregulation and functions of miRNAs have been extensively investigated in almost every biological process; however, the expression profiles and functions of the newly identified circRNAs in the specific biological activity still require further investigation.
circRNAs have been recently verified to be involved in developmental processes, regulation of cell function, pathogenesis of heart diseases, and development of neurodegenerative diseases like Alzheimer's disease. (5) In the study of carcinogenesis and progression, just like the extensive involvement of miRNAs in cancer, the expression profiles and the roles of circRNAs in cancer development and progression have attracted much attention as an emerging filed. Recently, certain kinds of circRNAs have been found to be significantly deregulated in gastric cancer, colorectal cancer, and esophageal squamous cancer, and these deregulated circRNAs are suggested to participate in cancer development. (6) (7) (8) These observations indicate that circRNAs may be a new kind of potential biomarkers and therapeutic targets for cancer; however, elucidating the deregulated circRNAs and identifying their functions is still an ongoing process in cancer investigation.
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide, especially in China. (9) Only 30%-40% of HCC patients are amenable to curative resection, owing partially to the late appearance of symptoms, and the prognosis of these HCC patients is still poor because of high frequency of metastasis and recurrence. These challenges give rise to the urgent need to identify potential biomarkers for prognosis predication and find new targets to design a more powerful therapeutic approach. In the last decade, numerous noncoding RNAs, including miRNAs and long noncoding RNAs, have been found to be deregulated in HCC patients, having potential applications in the clinic. However, the expression profile, function, and deregulation of circRNAs in HCC remain to be identified.
In our study, we analyzed the expression profile of circRNAs in HCC tissues and identified that circRNA circMTO1 (mitochondrial translation optimization 1 homologue; hsa_circRNA_0007874/hsa_circRNA_104135) is significantly down-regulated in HCC tissues and closely related to the prognosis of HCC patients. We found that circMTO1 may function as the sponge of oncogenic miR-9 to up-regulate p21 expression and consequently suppress HCC progression. Therefore, decrease of circMTO1 may serve as a biomarker for prognosis predication and as a potential therapeutic target for HCC patients.
Materials and Methods

TISSUES AND CELL LINES
The 289 samples of HCC and paired adjacent liver tissues were obtained from patients during operation. All samples were collected with the consent of patients, and the experiments were approved by ethics committee of Eastern Hepatobiliary Hospital (Shanghai, China). All tissue specimens were stored at 2808C until use. HCC cell lines HepG2, SMMC-7721, QGY-7701, and SK-Hep1 were cultured in
Dulbecco's modified Eagle's medium with 10% fetal bovine serum (Gibco, NY, USA) as routine. (10) 
EXPRESSION PROFILE ANALYSIS OF circRNAs
The circRNAs chip (Arraystar Human circRNAs chip; ArrayStar, Rockville, MD, USA), containing 5396 probes specific for human circRNAs splicing sites, was used. After hybridization and washing with samples, seven pairs of HCC samples (tumor tissues and matched nontumor tissues) were analyzed on the circRNAs chips. Exogenous RNAs developed by the External RNA Controls Consortium were used as controls. The Gene Expression Omnibus Accession number is GSE97332.
circRNAs IN VIVO PRECIPITATION (circRIP)
Biotin-labeled circMTO1 probe (5 0 -AAA GGA AGG ATT ACA TGA CAT CTG ACC CAA AAC AAC CCC ACT GAC A-3 0 -biotin) was synthesized by Sangon Biotech, and the circRIP assay was performed as previously described by us with minor modification. (11) CircMTO1-overexpressing HepG2 cells were fixed by 1% formaldehyde for 10 minutes, lysed, and sonicated. After centrifugation, 50 lL of the supernatant was retained as input and the remaining part was incubated with a circMTO1-specific probesstreptavidin dynabeads (M-280; Invitrogen) mixture overnight at 308C. On the next day, an M-280 dynabeads-probes-circRNAs mixture was washed and incubated with 200 lL of lysis buffer and proteinase K to reverse the formaldehyde cross-linking. Finally, the mixture was added with TRIzol for RNA extraction and detection. (11) 
SILENCING AND OVEREXPRESSION OF circMTO1
Small interfering RNA (siRNA) of circMTO1 was synthesized by GenePharma (Shanghai, China), targeting to the junction region of the circMTO1 sequence. HepG2 and SMMC-7721 cells were transfected with circMTO1 siRNAs or overexpressing plasmids using INTERFERin or jetPRIME (Polyplus transfection, France), respectively, as described. (12) The sequence of circMTO1 siRNA was 5 0 -UCU GAC CCA AAA CAA CCC CdTdT-3 0 .
REAL-TIME qRT-PCR ANALYSIS
Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). RNA concentration was measured by Nonodrop, and each paired sample was adjusted to the same concentration. Real-time qPCR was performed as described. (13, 14) Glyceraldehyde 3-phosphate dehydrogenase was used as the internal control. The primers are listed in Supporting Table S1 .
IN SITU HYBRIDIZATION
The expression level of circMTO1 in tissues was evaluated by in situ hybridization (ISH) using a specific digoxin-labeled circMTO1 probe on tissue arrays, which contained 116 HCC samples (Superchip Biotech, Shanghai, China). A quantitative scanning approach to evaluate staining and expression of circMTO1 was Aperio ImageScope V11 from Leica Company, (15, 16) and the positivity value 3100 represents the expression of circMTO1. The sequence of the circMTO1 probe for ISH was Digoxin-5 0 -CAT GAC ATC TGA CCC AAA ACA ACC-3 0 -Digoxin.
FLUORESCENCE IN SITU HYBRIDIZATION
Hybridization was performed overnight with circMTO1 and hsa-miR-9-5p probes. Specimens were analyzed on a Nikon inverted fluorescence microscope. The circMTO1 probe for fluorescence in situ hybridization (FISH) was 5 0 -GGA AGG ATT ACA TGA CAT CTG ACC CAA AAC AAC CCC ACT GAC-3 0 , and the hsa-miR-9-5p probe for FISH was 5 0 -TCT TTG GTT ATC TAG CTG TAT GA-3 0 .
HCC-BEARING NUDE MOUSE MODEL PREPARATION AND EXPERIMENTS IN VIVO
The HCC-bearing male nude mice model, SMMC-LTNM, were raised and passaged as described. (14, 17) At the third week after subcutaneous incubation of HCC tumor mass, 10 optical density cholesterol-modified circMTO1 siRNA, control siRNA (Ribobio, Guangzhou, China), or phosphate-buffered saline (PBS) were intratumorally injected every 3 days for 2 weeks. Tumor size was measured and serum alfa-fetoprotein (AFP) was detected using enzyme-linked immunosorbent assay (ELISA; Autobio, Zhengzhou, China). All animal experiments were undertaken in accord with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, with the approval of the Scientific Investigation Board of Second Military Medical University (Shanghai, China).
IMMUNOHISTOCHEMISTRY
Immunohistochemistry was performed as described. (18) Tissues sections were incubated with antibodies against p21 (CST, Danvers, MA, USA), matrix metalloproteinase 2 (MMP2; CST), or proliferating cell nuclear antigen (PCNA; CST) at 48C overnight. The ChemMate DAKO EnVision Detection Kit (Dako, Santa Clara, CA, USA) was used for immunostaining.
STATISTICAL ANALYSIS
The Student t test was performed to analyze whether two experimental groups have significant difference using P < 0.05 as the significant criteria. Survival analysis was performed by Kaplan-Meier curves and log-rank test for significance in GraphPad Prism 5.
Results
DEREGULATED circRNAs AND DECREASE OF circMTO1 IN HCC TUMOR TISSUES
To investigate circRNA expression profile in HCC tissues, we analyzed seven pairs of HCC tissue samples (seven HCC tissues and seven matched nontumor liver tissues) by using the CircRNA microArray (Supporting Fig. S1A ). Through expression intensity sorting within HCC tumor and nontumor groups, the 10 mostly increased and decreased circRNAs in HCC tumor tissues as compared to that in nontumor tissues are shown in Fig. 1A and Supporting Fig. S1B . Thus, the circRNA expression profiles of HCC and nontumor liver tissue were suggested in this study. Next, we examined the expression of these 20 mostly changed circRNAs in HCC and matched nontumor tissue samples from 21 patients to confirm their expression, and expression of the six mostly changed circRNAs are presented in Fig.  1B . Among them, we found that circMTO1 expression was consistently and significantly decreased in HCC tumor tissues as compared to that in matched controls (Fig. 1B) . Thus, we focused on the expression and role of circMTO1 in HCC progression in this study.
The expression of circMTO1 in HCC tissues was then confirmed in another 261 HCC patients, and the results showed that circMTO1 expression was significantly decreased in 87.4% (228 of 261) HCC tissues as compared to that in the matched nontumor tissues ( Fig. 2A,B) . Although some circRNAs, including circARID1B (ARID1B, AT-rich interaction domain 1B;), circFAM13B (family with sequence similarity 13 member B), and circFARP2 (FERM, ARH/RhoGEF and pleckstrin domain protein 2), were decreased in HCC tissues (Fig. 1B) , the preliminary results showed that silencing of these circRNAs had no significant effect on HCC cell growth (data not shown), and only silencing of circMTO1 had a significant effect to promote HCC cell proliferation. Therefore, the high percentage of circMTO1 decrease in HCC tissues inspired us to focus on the biological significance of circMTO1 in HCC progression.
DECREASED circMTO1 EXPRESSION IS SIGNIFICANTLY CORRELATED WITH POOR PROGNOSIS OF HCC PATIENTS
Because circMTO1 expression is significantly decreased in HCC tissues, we next analyzed whether circMTO1 decrease is correlated with the prognosis of HCC patients. A cohort of 116 HCC patients with survival data was included, and circMTO1 expression was determined using ISH analysis on tissue array slides. circMTO1 expression was also significantly decreased in HCC tissues as compared to that in matched nontumor tissues (Fig. 2C) . More important, decreased circMTO1 expression in HCC tissues was significantly correlated with poor prognosis of HCC patients, shown as Kaplan-Meier survival curve using median value of circMTO1 expression as the cut-off (Fig. 2D) . Furthermore, we also used the K-adaptive partitioning statistical (kaps) algorithm in R software to calculate the most efficient cut-off value of circMTO1 expression (76.89), (19) (20) (21) which can most significantly distinguish the outcomes of these HCC patients (Fig. 2E) . Together, these data suggest that decreased circMTO1 expression in HCC is correlated with poor prognosis of patients, and the circMTO1 expression value of 76.89 may be efficient in the prognosis prediction of HCC patients.
circMTO1 BINDS miR-9 IN HCC CELLS
Because circRNAs function mainly as miRNA sponges to bind functional miRNAs and then regulate gene expression, we next examined the potential miRNAs associated with circMTO1. Through MiRanda Program prediction, 99 miRNAs were predicated and listed as possible targets of circMTO1 (Supporting Table  S2 ). In order to fish out the functional miRNAs which may interact with circMTO1 in HCC cells, we used a circMTO1-specific probe to perform RNA in vivo precipitation (RIP), which we established before to identify the miRNAs actually binding with target mRNA. (11) We purified the circMTO1-associated RNAs by circMTO1-specific probe, and then screened the potential miRNAs which were predicted by the miRanda Program.
Among the 99 candidate miRNAs predicted by miRanda, we mainly screened and analyzed 20 miRNAs, whose expression and function have been implicated in HCC, including miR-204, miR-760, miR-4476, miR-6876, miR-152, miR-3686, miR-3159, miR-199a, miR181a-2, miR-211, miR-218-2, miR3155a, miR-6730, miR-15a, miR-199b, miR-223, miR-3156, miR-4286, miR-4302, and miR-9 (Supporting Fig. S2 ). By RIP circMTO1 pull-down experiments, we purified the circMTO1-associated RNAs and analyzed the 20 candidate miRNAs in the complex. We found a specific enrichment of circMTO1 and miR-9 as compared to the controls (Fig. 3A,B) , whereas the other miRNAs had no enrichment (Supporting Fig.  S2 ), determining that miR-9 is the circMTO1-associated miRNA in HCC cells. Although the controversial roles of miR-9 in promoting or inhibiting tumor growth were reported, (22) (23) (24) miR-9 was frequently found to be increased in HCC and its increased expression was closely correlated with poor prognosis of HCC patients. (25, 26) Thus, the interaction between miR-9 and circMTO1 was then focused on and investigated. By FISH analysis in HCC tumor and matched nontumor tissues, we found that circMTO1 was colocalized with miR-9 in the cytoplasm and this colocalization was decreased in tumor as compared to that in matched nontumor tissues (Fig. 3C) . Together, these results suggest that circMTO1 can bind miR-9 in the cytoplasm.
circMTO1 INHIBITS PROLIFERATION AND INVASION OF HCC CELLS IN VITRO
The roles of circMTO1 in HCC progression were then investigated. To choose the HCC cell lines used for silencing or overexpression of circMTO1, we checked the expression of circMTO1 and miR-9 in eight HCC cell lines. SK-Hep1 cells showed the lowest expression of circMTO1 and the highest expression of miR-9, QGY-7701 cells showed moderate expression of the two RNAs, and HepG2 and SMMC-7721 cells showed higher expression of circMTO1 and lower expression of miR-9 (Supporting Fig. S3A ). Therefore, HepG2 and SMMC-7721 cells were selected for silencing of circMTO1, and SK-Hep1 and QGY-7701 cells were selected for overexpression of circMTO1. We constructed siRNA, which covers the back-splicing region of circMTO1 for silencing. After transfection with circMTO1 siRNA into HepG2 and SMMC-7721 HCC cells, the efficiency of circMTO1 silencing was measured and confirmed by qPCR (Supporting Fig.  S3B ). To convincingly show that our transfection had no effects on other MTO1 splicing products, qPCR was performed to detect expression of another circMTO1 (has_circRNA_0132266, isoform2) and mRNA level of MTO1 (linearMTO1). The expression of circMTO1 isoform2 (has_circRNA_0132266) and MTO1 mRNA showed no significant change after transfection of circMTO1 siRNA, confirming the specificity of circMTO1 silencing (Supporting Fig. S3C ). In addition, we constructed the circMTO1 overexpressing plasmid (pCD-circMTO1) with circular frame and circMTO1 sequence, and found that circMTO1 could be significantly overexpressed in QGY-7701 and SKHep1 HCC cells (Supporting Fig. S3D ).
Silencing of circMTO1 was performed in HCC cells to determine its effect on HCC progression and to investigate its interaction with miR-9 (Fig. 4A, Supporting  Fig. S3B ). circMTO1 silencing significantly promoted cell proliferation (Fig. 4B) , enhanced cell invasion (Fig.  4C) , and reduced apoptosis (Fig. 4D ) of HepG2 and SMMC-7721 cells, respectively, whereas circMTO1 overexpression promoted apoptosis of QGY-7701 and SK-Hep1 HCC cells (Fig. 4D) . Moreover, miR-9 overexpression photocopied the tumor-promoting effects of circMTO1 silencing in HepG2 and SMMC-7721 (Fig.  4B-D) . To verify the miRNA sponge function of circ-MOT1, we examined miR-9 expression and found that circMTO1 had no effect on the expression level of miR-9 (Supporting Fig. S4A,B) . Thus, these results suggest that circMTO1 suppresses HCC progression possibly by reducing the oncogenic effect of miR-9 by sponge activity.
circMTO1 SUPPRESSES HCC GROWTH BY SPONGE ACTIVITY OF miR-9 AND UPREGULATION OF p21
In order to investigate whether circMTO1 exerts its antitumor effect through sponge activity of miR-9, we examined the expression of tumor suppressor p21, the target of miR-9. (27) (28) (29) (30) Both silencing of circMTO1 or transfection of miR-9 mimic significantly reduced mRNA and protein expression levels of p21 in HCC cells (Fig. 4E,F) . In addition, overexpression of circMTO1 could increase the mRNA and protein expression levels of p21 in QGY-7701 and SK-Hep1 HCC cells (Fig. 4E,F) . These results suggest that circMTO1 may exert its antitumor effect through protecting p21 from down-regulation by miR-9.
In order to functionally confirm that circMTO1 suppresses HCC progression by sponge activity of miR-9 and consequently up-regulating p21, miR-9 inhibitor was used to examine whether the tumorpromoting effect of circMTO1 silencing could be blocked by miR-9 knockdown. miR-9 inhibitor could significantly reduce the down-regulation of p21 mRNA and protein expression after silencing of circMTO1 (Fig. 5A-C) . More important, miR-9 inhibitor significantly blocked the circMTO1   FIG. 3 . circMTO1 binds miR-9 in HCC cells. (A) circMTO1 in HCC cell lysis was pulled down and enriched with circMTO1 specific probe and then detected by qPCR. (B) miR-9 was pulled down and enriched with a circMTO1-specific probe and then detected by qPCR. (C) miR-9 colocalized with circMTO1 in HCC adjacent nontumor and tumor tissues were detected by FISH. Data are from three independent experiments (mean 6 SEM; A,B) or are representative of three independent experiments with similar results (C). Magnification, 3400. *P < 0.05; **P < 0.01. Abbreviation: DAPI, 4 0 ,6-diamidino-2-phenylindole. silencing-mediated promotion of proliferation and inhibition of apoptosis, of HCC cells (Fig. 5D,E) . So, miR-9 inhibitor could block the HCC-promoting effect of circMTO1 silencing. These data convincingly demonstrate that circMTO1 suppresses HCC progression as a sponge of miR-9 to eliminate the miR-9 oncogenic effect through circMTO1/miR-9/p21 axis.
INTRATUMORAL KNOCKDOWN OF circMTO1 ENHANCES HCC GROWTH IN VIVO
We next investigated the significance of circMTO1 silencing in HCC growth in vivo. HCC-bearing nude mice (SMMC-LTNM) were initially prepared by transplanting human HCC tissues to form subcutaneous tumor in nude mice and maintained with continuously subcutaneous passage. (11) After continuous intratumoral injection of cholesterol-conjugated circMTO1 siRNAs for 2 weeks, we found that tumor growth was significantly accelerated and serum AFP was markedly increased in HCC-bearing SMMC-LTNM mice (Fig. 6A,B) . The expression of circMTO1 and p21 was markedly reduced in tumor tissues of SMMC-LTNM mice 48 hours after intratumoral injection of cholesterol-conjugated circMTO1 siRNAs (Fig. 6C) . Moreover, p21 and downstream CDK2 expressions were inhibited by in vivo circMTO1 knockdown, whereas cell invasion and proliferation markers MMP2 and PCNA were upregulated ( Fig. 6D and Supporting Fig. S4C ). Thus, these results demonstrate that circMTO1 can suppress HCC progression in vivo.
Discussion
The roles of circRNAs in carcinogenesis and cancer progression have attracted much attention currently. Because their expression and function in HCC development are still largely elusive, we screened the differentially expressed circRNAs between HCC and matched nontumor liver tissues through chip microArray and focused on the role and underlying mechanism of the decreased circMTO1 expression in HCC progression. Although the tumor-inhibitory effects of circMTO1 in HCC were suggested in this study, we do not exclude the possibility that there may be other important deregulated circRNAs, which also participate in the development of HCC, because of the limited HCC tissue samples we screened at the beginning. Hence, the deregulated circRNAs in HCC pathology still need further investigation, and we will keep focusing on this issue in our future studies.
The decreased circMTO1 expression in HCC was determined to be significantly correlated with prognosis of HCC patients, and by using kaps algorithm, we obtained an efficient cut-off value of circMTO1 (76.89) in distinguishing the outcomes of HCC patients. Although the exact applicable cut-off value still needs to be confirmed in a large set of patients, the circMTO1 expression value of 76.89 is somewhat practical in the prognosis prediction of HCC patients. Currently, a set of intracellular gene expression, including coding genes and noncoding RNAs, have been determined to be correlated with prognosis of HCC patients. (12, 14) However, a conclusive or practical criterion for the identification of HCC prognosis still requires further investigation. Quantitative examination of the expression and combined detection of these genes associated with prognosis may have considerable potential in the accurate identification and prediction of prognosis in HCC patients. Moreover, because some of the noncoding RNAs, especially miRNAs, are stable in plasma, they can be the biomarkers for HCC diagnosis and treatment, (12, 14, (31) (32) (33) and some circular RNAs are enriched in exosomes. (34) Whether circMTO1 can also be detected in plasma or even in circulating exosomes and whether the circulating circMTO1 is also associated with HCC development are interesting and important questions for circRNA study, which require further investigation.
The mechanisms for circRNA function in carcinogenesis and cancer progression have not been elucidated very clearly. circRNAs may regulate the expression of oncogenic or tumor suppressive genes through different targets, depending on the different types of cancer or even at different stages. (35) The most reported function pattern for circRNAs is acting as a miRNA sponge and forming the circRNA-miRNAmRNA axis. (3, 36) For example, circRNA SRY was reported to be a tumor-related molecule in colorectal cancer and ovarian cancer by absorbing miR-138. (37) cir-ITCH functions as a sponge of miR-7, miR-17, and miR-214 to suppress the wnt/b-catenin pathway, (8) and ciRS-7 participates in gastric cancer and colorectal cancer by interacting with miR-7. (38) (39) (40) (41) Together with miRNAs and their targetome, the circRNA-miRNA-mRNA axis may function as an extensive regulatory network in gene expression, and their deregulation may cause disease progression including cancer development. This presumption may raise interesting future works to elucidate the regulatory network of noncoding RNAs and coding genes in cancer biology.
At present, miRNAs targeted by circRNAs are mostly predicted and selected by computational algorithms, which seems to be shortsighted. How to , and PCNA expression in SMMC-LTNM tumor tissues after intratumoral circMTO1 knockdown at the fifth week. Data are from three independent experiments (mean 6 SEM; A-C) or are representative of three independent experiments with similar results (D). Magnification, 3200. *P < 0.05; **P < 0.01. precisely figure out which miRNA truly binds to a particular circRNA is important for the investigation of mechanisms of circRNA functions. We previously established miRIP as providing an effective way of quickly finding miRNAs that can be interacted by the interested RN. (11) Using the miRIP approach, the potential interaction between miR-92a and p21, and between miR-197 and signal transduction and activator of transcription 3, were elucidated by our previous study. (11, 42) In this study, by performing RIP using a circMTO1-specific probe, we found that miR-9 was the circMTO1-binding miRNA and then functionally proved that circMTO1 functioned as the sponge of the miR-9. Thus, the miRIP approach would be a practical and useful method to identify the true and definite interaction between miRNAs and circRNAs, especially considering that the circRNA-miRNA interaction network is relatively complicated.
In summary, our findings reveal that circMTO1 expression is significantly decreased in HCC and correlated with poor prognosis of HCC patients. Functionally and mechanistically, circMTO1 inhibits HCC growth by the sponge activity on miR-9 and upregulation of p21 expression, indicating its tumor suppressive role in HCC development. Furthermore, the in vivo intervention of circMTO1 indicates its potential in HCC-targeted therapy. Our data suggest that circMTO1 may have considerable potential as a prognosis predictor and therapeutic target for HCC.
